OPTIMAL SERUM-CHOLESTEROL LEVELS AND EFFICACY OF METHODS DESIGNED TO LOWER THE SERUM-CHOLESTEROL

被引:0
作者
EMMERICH, J
THOMAS, D
RICHARD, JL
DELAHAYE, F
BRUCKERT, E
机构
[1] HOP BROUSSAIS, CTR CLAUDE BERNARD RECH MALAD VASC PERIPHERIQUES, F-75674 PARIS 14, FRANCE
[2] GRP HOSP PITIE SALPETRIERE, SERV CARDIOL, F-75634 PARIS 13, FRANCE
[3] HOP BROUSSAIS, INSERM, U258, F-75674 PARIS 14, FRANCE
[4] HOP CARDIOVASC & PNEUMOL LOUIS PRADEL, SERV CARDIOL, F-69394 LYON 3, FRANCE
[5] GRP HOSP PITIE SALPETRIERE, SERV ENDOCRINOL METAB, F-75634 PARIS 13, FRANCE
来源
ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX | 1992年 / 85卷
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Analysis of epidemiological studies enables definition of the optimal serum cholesterol level between 2 and 2.2 g/l (5.2 and 5.7 mmol/l). Higher levels are associated with an exponential risk of coronary artery disease: lower levels should be interpreted with caution because of the J-shaped curve of global mortality reported in several trials. In primary prevention, therapeutic trials have clearly shown that a significant reduction in the number of coronary event may be obtained by lowering the serum cholesterol (15 for every 1 000 patients treated). In trials performed to date this benefit has not resulted in any gain in global mortality. In secondary prevention, the benefits of lowering serum cholesterol on the incidence of coronary disease seems identical in terms of relative risk to that observed in primary prevention. Nevertheless, the benefits in terms of absolute risk are much higher because of the high incidence of coronary mortality in a patient population with a previous coronary event. Thus, for 1 000 patients treated, there are 50 less cardiac events and this is reflected in a reduction of global mortality of about 20 for every 1 000 patients treated.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 54 条
[1]   1ST MYOCARDIAL-INFARCTION - AGE AND EJECTION FRACTION IDENTIFY A LOW-RISK GROUP [J].
AHNVE, S ;
GILPIN, E ;
DITTRICH, H ;
NICOD, P ;
HENNING, H ;
CARLISLE, J ;
ROSS, J .
AMERICAN HEART JOURNAL, 1988, 116 (04) :925-932
[2]   CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY [J].
ANDERSON, KM ;
CASTELLI, WP ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16) :2176-2180
[3]  
[Anonymous], 1965, LANCET, V2, P501
[4]  
[Anonymous], 1968, LANCET, V2, P693
[5]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[6]  
[Anonymous], 1986, Am J Cardiol, V58, P1
[7]  
BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080
[8]  
BLACKBURN H, 1979, PREV MED, V8, P609
[10]   EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
VARCO, RL ;
MATTS, JP ;
LONG, JM ;
FITCH, LL ;
CAMPBELL, GS ;
PEARCE, MB ;
YELLIN, AE ;
EDMISTON, WA ;
SMINK, RD ;
SAWIN, HS ;
CAMPOS, CT ;
HANSEN, BJ ;
TUNA, N ;
KARNEGIS, JN ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
BISSETT, JK ;
WEBER, FJ ;
STEVENSON, JW ;
LEON, AS ;
CHALMERS, TC .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955